TOL
Sign in
Toleranzia AB
Save
158.24M
Market cap
–
Current P/E
4.06x
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.
Similar securities
Based on sector and market capitalization
Report issue